X

Watch: Biomarkers in drug development with Dr. Bernie Zeiher

Andrew Powaleny   |     February 14, 2017   |   SHARE THIS

Biomarkers are powerful tools which are used by medical professionals in many ways, including in the diagnosis of disease, monitoring how a disease is progressing and, if a treatment is given, how the body is responding. Biomarkers may also help biopharmaceutical researchers determine which medicines may be most effective in certain patients. In a new series of videos Dr. Bernie Zeiher, president of development at Astellas Pharma, discusses how scientists are using biomarkers to create more precise, personalized treatment approaches for patients.

“Biomarkers are used in clinical studies to select patients eligible to be treated in that study,” explains Zeiher. “In the case of oncology, if you’re targeting a tumor that has a particular mutation, you’d run the test before they’re enrolled and see if they have that mutation, and if they are, they’re eligible for treatment.” 

The latest iteration of the Prescription Drug User Fee Act enhances the FDA’s biomarker qualification pathway and establishes a dedicated process to improve the use of biomarkers as surrogate endpoints in drug development.

To hear more from Dr. Zeiher on how biomarkers are advancing personalized medicines and helping improve outcomes for patients, explore the video series below.

The Role of Biomarkers in Clinical Trials:

 

Using Biomarkers to Determine Medicines’ Effectiveness:

 

Using Biomarkers to Select Clinical Trial Participants:

 
Andrew Powaleny

Andrew Powaleny is Senior Director of Public Affairs at PhRMA and leads the organizations scientific communications. Before joining PhRMA in 2015, he worked in public affairs for a small firm in Washington, DC and served as Deputy Press Secretary for the House Committee on Energy and Commerce. Andrew came to Washington, D.C. via Connecticut with a degree from Eastern Connecticut State University where he majored in public policy and government. Andrew is active as a runner and volunteer with the DC Front Runners; most recently serving on its Board of Directors for three years as co-race director. He is also a member of the NLGJA: The Association of LGBTQ Journalists and mentors students through his alumni association with The Fund for American Studies. Andrew is passionate about scientific innovation, especially for mental illness, and his heroes are the men and women of America’s biopharmaceutical research companies.

Topics: Research and Development, PhRMA Member Company, Clinical Trials

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates